IPL344 is Immunity Pharma's lead drug candidate. IPL344 was discovered in the Weizmann institute of Science, Israel, at Prof. Irun Cohen's Laboratory. IPL344 is being developed as an intravenous ...

After much anticipation, As ever's first seasonal drop will be available today for purchase at AsEver.com.

Reduction of the company's own CO₂e emissions by around 18 percent compared to the base year 2020 ...

Leveraging Infosys Topaz, the Stats Center offers interactive and immersive stories based on driver and team stats across ...

Incoming Orders/Expansion Steyr Motors AG underpins its internationalisation strategy with order from India 02.04.2025 / 10:15 CET/CEST The issuer is solely responsible for the content of this ...

AI drug design engine and advance therapeutic progra London (OTE) - Isomorphic Labs will utilise the funding to further power its AI drug design engine through frontier AI research and development and ...

Alliance/ESG Wolftank Group builds first hydrogen refueling station for ACTIVA project in Spain 01.04.2025 / 09:00 CET/CEST The issuer is solely responsible for the content of this announcement.

“Removing journalistic content doesn’t just strip away information—it erodes trust,” says the FehrAdvice research team. “Users rated Google as less credible, less trustworthy, and less complete ...

EQS-News: Andritz AG / Announcement of the Results of the General Meeting ANDRITZ AG’s Annual General Meeting approves dividend of EUR 2.60 per share 27.03.2025 / 13:29 CET/CEST Announcement of the ...

Isomorphic Labs will utilise the funding to further power its AI drug design engine through frontier AI research and development and to scale and progress its drug candidate pipeline. Isomorphic Labs, ...

Annual Results Innovating for a better future – wienerberger’s 2024 Annual Report published 31.03.2025 / 08:30 CET/CEST The issuer is solely responsible for the content of this announcement.

Sustainability Lenzing AG as a European pioneer for a clean industry at Hannover Messe 2025 31.03.2025 / 09:05 CET/CEST The issuer is solely responsible for the content of this announcement.